The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.

[1]  R. Dummer,et al.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. , 2015, The Lancet. Oncology.

[2]  A. Hauschild,et al.  Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. , 2015, The Lancet. Oncology.

[3]  A. Hauschild,et al.  Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. , 2015, Journal of the American Academy of Dermatology.

[4]  V. Sondak,et al.  Composite assessment of treatment response in patients (pts) with locally advanced basal cell carcinoma (laBCC): Sonidegib efficacy using two sets of response criteria. , 2015 .

[5]  R. Dummer,et al.  Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma , 2015, Clinical Cancer Research.

[6]  M. Hidalgo,et al.  Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[7]  A. El-Khoueiry,et al.  A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[8]  A. Wysong,et al.  An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. , 2014, Journal of the American Academy of Dermatology.

[9]  R. Dummer,et al.  Basal cell carcinomas in a tertiary referral centre: a systematic analysis , 2014, The British journal of dermatology.

[10]  R. Dummer,et al.  Emerging drugs and combination strategies for basal cell carcinoma , 2014, Expert opinion on emerging drugs.

[11]  K. Peris,et al.  Update of the European guidelines for basal cell carcinoma management , 2014, European Journal of Dermatology.

[12]  R. Dummer,et al.  A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[13]  J. Blay,et al.  GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Prados,et al.  A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B). , 2013 .

[15]  C. Rudin,et al.  Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors , 2013, Clinical Cancer Research.

[16]  Aleksandar Sekulic,et al.  Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway , 2013, Current Opinion in Oncology.

[17]  L. Siu,et al.  The utility of hedgehog signaling pathway inhibition for cancer. , 2012, The oncologist.

[18]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[19]  Kris Chang,et al.  Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. , 2012, The New England journal of medicine.

[20]  C. Rudin,et al.  Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[21]  Lixin Lang,et al.  A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. , 2010 .

[22]  P. LoRusso,et al.  Review: Targeting the Hedgehog pathway in cancer , 2010, Therapeutic advances in medical oncology.

[23]  M. Warmuth,et al.  Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. , 2010, ACS medicinal chemistry letters.

[24]  L. Schwartz,et al.  32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1 , 2008 .

[25]  Lee L. Rubin,et al.  Targeting the Hedgehog pathway in cancer , 2006, Nature Reviews Drug Discovery.

[26]  W. Sterry.  Guidelines: the management of basal cell carcinoma. , 2006, European journal of dermatology : EJD.

[27]  M. Wolter,et al.  Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas , 2005, The British journal of dermatology.

[28]  Michael Dean,et al.  Is human patched the gatekeeper of common skin cancers? , 1996, Nature Genetics.

[29]  M. Hidalgo,et al.  Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors , 2015 .

[30]  L. Kux.  OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .

[31]  J. Hainsworth,et al.  Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. , 2014, Journal of the American Academy of Dermatology.